{"id":893680,"date":"2025-10-08T08:26:27","date_gmt":"2025-10-08T12:26:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-and-childrens-hospital-colorado-announce-newest-treatment-center-for-zevaskyn-gene-therapy\/"},"modified":"2025-10-08T08:26:27","modified_gmt":"2025-10-08T12:26:27","slug":"abeona-therapeutics-and-childrens-hospital-colorado-announce-newest-treatment-center-for-zevaskyn-gene-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-and-childrens-hospital-colorado-announce-newest-treatment-center-for-zevaskyn-gene-therapy\/","title":{"rendered":"Abeona Therapeutics\u00ae and Children’s Hospital Colorado Announce Newest Treatment Center for ZEVASKYN\u00ae Gene Therapy"},"content":{"rendered":"
\n

CLEVELAND, Ohio and AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) and Children’s Hospital Colorado today announced activation of Children’s Colorado as the newest Qualified Treatment Center (QTC) for ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. This first-of-its-kind therapy is FDA-approved to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Children’s Colorado in Aurora, CO, one of the pioneering institutions that provide advanced levels of care for people with epidermolysis bullosa (EB), has completed QTC start-up activities enabling it to begin patient identification for scheduling of ZEVASKYN treatment.<\/p>\n

Anna L. Bruckner, MD, Co-Director of the EB Clinic at Children\u2019s Hospital of Colorado and Professor of Dermatology, University of Colorado School of Medicine, said, \u201cWe are thrilled to be able to provide our patients a much needed, long lasting treatment option, and with it, the hope for an improved quality of life.\u201d<\/p>\n

\u201cWe are excited to be working with Dr. Bruckner and Children’s Hospital Colorado in making ZEVASKYN available to RDEB patients,\u201d said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. \u201cDr. Bruckner is one of the leading experts in EB care, and the activation of Children\u2019s Colorado is a major milestone in broadening access to ZEVASKYN across a growing network of established EB centers.\u201d<\/p>\n

Children\u2019s Hospital Colorado\u2019s epidermolysis bullosa program is recognized as a center of excellence by debra of America, the lead patient advocacy organization for EB. Children’s Colorado is a member of the EB Clinical Research Consortium and continues to conduct cutting-edge bench and clinical research to reshape the future of rare disease treatment and offer significant promise of transformative care and better quality of life for patients with EB. The Precision Medicine Institute at Children\u2019s Colorado supports these programs through pioneering novel treatments like this, using each patient\u2019s unique genetic information to treat their disease.<\/p>\n

For more information on how to access ZEVASKYN and learn about patient support services offered through Abeona Assist\u2122, Abeona\u2019s comprehensive patient support program, visit www.abeonaassist.com<\/a>, call 1-855-ABEONA-1 (1-855-223-6621) or email MyNavigator@AbeonaAssist.com<\/a>. Abeona Assist offers personalized support, including helping eligible patients understand their insurance benefits and financial assistance options, and providing travel and logistical assistance.<\/p>\n

\n About recessive dystrophic epidermolysis bullosa <\/strong><\/p>\n

Recessive dystrophic epidermolysis bullosa (RDEB), a rare blistering disorder without a cure, is characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. People with RDEB have a defect in both copies of the COL7A1 gene, leaving them unable to produce functioning type VII collagen, which is necessary to anchor the dermal and epidermal layers of the skin.<\/p>\n

\n About ZEVASKYN<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n (prademagene zamikeracel) gene-modified cellular sheets <\/strong><\/p>\n

ZEVASKYN is the first and only autologous cell sheet-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a severe skin disease caused by a defect in both copies of the COL7A1 gene resulting in the inability to produce functional type VII collagen. Without functional type VII collagen and anchoring fibrils, the skin is fragile and blisters easily, leading to wounds that continually open and close, or fail to heal altogether. Patients often have large open wounds that can lead to serious life-threatening complications. ZEVASKYN incorporates the functional type VII collagen-producing COL7A1 gene into a patient\u2019s own skin cells, ex vivo, using a replication-incompetent retroviral vector to produce functional type VII collagen in treated wounds. ZEVASKYN has demonstrated clinically meaningful wound healing and pain reduction with a single surgical application. For more information, visit www.ZEVASKYN.com<\/u><\/a>.<\/p>\n

\n Indication<\/strong>\n <\/p>\n

ZEVASKYN\u00ae<\/strong><\/sup> (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).<\/p>\n

\n Important Safety Information<\/strong>\n <\/p>\n